Short interest for Inovio Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Inovio Pharmaceuticals's stock. Short interest data is updated every two weeks.

Inovio Pharmaceuticals Stock (NASDAQ:INO), Short Interest Report

Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACDC

ADXN

BACK

BENF

BNED

BSGM

CGEM

CLDI

CSLR

CTNM

DFLI

DYNT

ERIC

ITCI

JAGX

KAVL

MCBC

MNSO

PACB

PALI

PRFX

PRSO

PRZO

RNAC

RVYL

SKIL

SMXT

SPRC

SXTC

SYTA

TAOP

WISA

WFTC

Shares of  Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

stock chart-1863880_1920-60

Offerings

Inovio announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share. 

Inovio Pharmaceuticals Stock Is Diving Today: What&#39;s Happening?

Pre-Market Outlook

ENSV

GRPN

KXIN

SHPH

SPCB

USEG

Shares of  Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corporation (NASDAQ: WFTC) and Macatawa Bank announced that they have entered into a definiti

Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals Inc

Innodata Inc

IN OVATIONS HOLDINGS INC by In Ovations Holdings, Inc.

In Ovations Holdings Inc

TPT Strategic Inc

Predictiv AI Inc

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

InfoNow Corp

Inovio Pharmaceuticals Form 13G Shows Deep Track Capital, LP Reported A 9.99% Stake In The Co As Of April, 16, 2024

Shares of Skillsoft Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skil#NASDAQ">SKIL</a>) fell sharply during Tuesday&rsquo;s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
Skillsoft posted adjusted loss of $3.09 per share, versus market estimates of $3.27 per share. The company&rsquo;s quarterly sales came in at $137.540 million versus expectations of $141.897 million.
Skillsoft shares dipped 26.7% to $6.74 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) jumped 85% to $3.2379 after the company announced a 5-year WiSA E licensing agreement with an HDTV/PTV brand.</li>
<li>Palisade Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pali#NASDAQ">PALI</a>) shares climbed 79.1% to $7.45 after the company announced the completion of analysis evaluating ex-vivo bioactivation of PALI-2108.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) shares gained 67% to $0.1989 after the company signed an exclusive 5-year in-license agreement with Venture Life Group for Gelclair.</li>
<li>Dynatronics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dynt#NASDAQ">DYNT</a>) shares rose 44.4% to $0.5342 after dipping over 5% on Monday.</li>
<li>IMAC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/back#NASDAQ">BACK</a>) surged 40% to $4.69.</li>
<li>Peraso Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prso#NASDAQ">PRSO</a>) gained 38.8% to $1.75. Peraso recently announced that it received an additional $2.88 million purchase order.</li>
<li>Macatawa Bank Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcbc#NASDAQ">MCBC</a>) rose 38.8% to $13.78 after Wintrust Financial Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wftc#NASDAQ">WFTC</a>) and Macatawa Bank announced that they have entered into a definitive merger agreement for Wintrust to acquire Macatawa in an all-stock transaction.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtc#NASDAQ">SXTC</a>) jumped 29.9% to $1.52.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dfli#NASDAQ">DFLI</a>) gained 26.7% to $0.57 after the company posted a profit for the fourth quarter.</li>
<li>Intra-Cellular Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/itci#NASDAQ">ITCI</a>) gained 24.1% to $80.39 after the company announced Lumateperone 42 mg once daily as adjunctive therapy to antidepressants met its primary endpoint.</li>
<li>Cullinan Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgem#NASDAQ">CGEM</a>) jumped 20.4% to $19.93. The company announced its plan to expand into autoimmune diseases.</li>
<li>Taoping Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/taop#NASDAQ">TAOP</a>) shares gained 14.1% to $0.97 after dipping 20% on Monday.</li>
<li>BioSig Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bsgm#NASDAQ">BSGM</a>) climbed 13.1% to $1.2439.</li>
<li>NextNav Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nn#NASDAQ">NN</a>) gained 13.1% to $7.98.</li>
<li>UnitedHealth Group Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>) jumped 6.2% to $473.20 following better-than-expected first-quarter earnings.</li>
<li>Contineum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctnm#NASDAQ">CTNM</a>) gained 6.1% to $15.50.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eric#NASDAQ">ERIC</a>) rose 4.7% to $5.01 after the company reported better-than-expected first-quarter EPS results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Barnes &amp; Noble Education, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bned#NYSE">BNED</a>) shares dipped 58.2% to $0.2947 after the company announced a short-term shareholder rights plan and a new equity investment.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) fell 54.8% to $0.2711 after the company announced the pricing of a $6.1 million public offering.</li>
<li>Nexalin Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxl#NASDAQ">NXL</a>) fell 46% to $1.07.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>) fell 40.2% to $1.6999 after the company issued weak guidance.</li>
<li>Ryvyl Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvyl#NASDAQ">RVYL</a>) fell 29.3% to $1.44 after the company announced the launch of a proposed underwritten public offering.</li>
<li>Beneficient (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/benf#NASDAQ">BENF</a>) dipped 25% to $0.0676. Beneficient announced a reverse stock split to regain compliance with Nasdaq&#39;s minimum bid price.</li>
<li>PainReform Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prfx#NASDAQ">PRFX</a>) fell 23.3% to $0.7515 after the company priced its $4 million public offering.</li>
<li>Siyata Mobile Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/syta#NASDAQ">SYTA</a>) dipped 23.3% to $2.46. Siyata Mobile filed for offering of maximum of $4 million of common shares.</li>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kavl#NASDAQ">KAVL</a>) fell 22.2% to $4.90.</li>
<li>ParaZero Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/przo#NASDAQ">PRZO</a>) fell 18% to $0.91 after the company announced its intention to enter the counter unmanned aircraft system market.</li>
<li>Complete Solaria, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cslr#NASDAQ">CSLR</a>) dipped 16.5% to $0.2167.</li>
<li>SolarMax Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) fell 13.4% to $12.91.</li>
<li>Addex Therapeutics Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adxn#NASDAQ">ADXN</a>) declined 10.8% to $22.07 after falling around 3% on Monday.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ino#NASDAQ">INO</a>) shares declined 10.3% to $9.87. INOVIO priced its $36 million underwritten offering of 2,536,258 common stock at $7.693 per share.</li>
<li>First Majestic Silver Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ag#NYSE">AG</a>) fell 10.2% to $6.72.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) fell 10.1% to $1.33 after declining around 6% on Monday. The company recently announced the acquisition of AutoMax.</li>
<li>Qilian International Holding Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qli#NASDAQ">QLI</a>) fell 9.1% to $0.6303 after declining around 8% on Monday.</li>
<li>ProFrac Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acdc#NASDAQ">ACDC</a>) fell 8.6% to $7.76.</li>
<li>Adlai Nortye Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anl#NYSE">ANL</a>) declined 7.4% to $9.80.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnac#NASDAQ">RNAC</a>) fell 6.9% to $17.69.</li>
<li>MINISO Group Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnso#NASDAQ">MNSO</a>) fell 6.8% to $19.33.</li>
<li>ArcelorMittal SA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mt#NYSE">MT</a>) shares fell 6.6% to $25.16 after Deutsche Bank downgraded the stock from Buy to Hold.</li>
<li>Live Nation Entertainment, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lyv#NYSE">LYV</a>) fell 5.8% to $94.00 following a report indicating the Justice Department will file an antitrust lawsuit against the company.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38271269/dow-gains-over-100-points-bank-of-america-posts-upbeat-profit"> Dow Gains Over 100 Points; Bank of America Posts Upbeat Profit</a>

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares are trading lower Tuesday after the company announced the <a href="https://www.benzinga.com/pressreleases/24/04/n38260980/inovio-announces-pricing-of-approximately-36-million-underwritten-offering-of-common-stock-and-pre">pricing of a public offering</a>.
What Happened: Inovio announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of&nbsp;$7.693&nbsp;per share. The company will also offer pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of&nbsp;$7.692&nbsp;per pre-funded warrant.
All of the securities are being offered and sold by Inovio. The offering is expected to close on or about April 18. Inovio said it anticipates gross proceeds of approximately $36 million.
Inovio is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. 
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38266919/whats-going-on-with-italian-energy-company-eni-shares-today">What&#8217;s Going On With Italian Energy Company Eni Shares Today?</a>
<h2 class="wp-block-heading">How To Buy INO Stock</h2>
By now you're likely curious about how to participate in the market for Inovio &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. In the case of Inovio, which is trading at $8.38 as of publishing time, $100 would buy you 11.93 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
INO Price Action: Inovio shares were down 23.9% at $8.36 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: 3844328 from Pixabay.

Inovio Pharmaceuticals Stock Is Diving Today: What's Happening?

WIIM

INOVIO shares are trading lower after the company announced the pricing of its $36 million underwritten offering.

Shares of Macatawa Bank Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcbc#NASDAQ">MCBC</a>) rose sharply in today&rsquo;s pre-market trading after Wintrust Financial Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wftc#NASDAQ">WFTC</a>) and Macatawa Bank announced that they have entered into a definitive merger agreement for Wintrust to acquire Macatawa in <a href="https://www.benzinga.com/m-a/24/04/38259312/macatawa-bank-stock-soars-on-merger-agreement-whats-going-on">an all-stock transaction</a>.
Macatawa Bank shares jumped 37% to $13.60 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Dynatronics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dynt#NASDAQ">DYNT</a>) shares rose 69.8% to $0.6301 in pre-market trading after dipping over 5% on Monday.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dfli#NASDAQ">DFLI</a>) gained 55% to $0.6974 in pre-market trading after the company posted a profit for the fourth quarter.</li>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) shares gained 34.2% to $2.35 in pre-market trading after falling around 23% on Monday.</li>
<li>Mobilicom Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mob#NASDAQ">MOB</a>) shares gained 24.8% to $1.56 in pre-market trading.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shph#NASDAQ">SHPH</a>) gained 19.5% to $0.4895 in pre-market trading.</li>
<li>Taoping Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/taop#NASDAQ">TAOP</a>) shares gained 17.7% to $1.00 in pre-market trading after dipping 20% on Monday.</li>
<li>SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) shares rose 17.4% to $0.47 in pre-market trading after jumping 45% on Monday.</li>
<li>Kaixin Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kxin#NASDAQ">KXIN</a>) shares gained 15.6% to $0.1735 in pre-market trading after dipping 16% on Monday.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eric#NASDAQ">ERIC</a>) rose 7.7% to $5.16 in today&rsquo;s pre-market trading after the company reported better-than-expected first-quarter EPS results.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>Ryvyl Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvyl#NASDAQ">RVYL</a>) fell 38.7% to $1.25 in pre-market trading after the company announced the launch of a proposed underwritten public offering.</li>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ino#NASDAQ">INO</a>) shares declined 24.3% to $8.32 in pre-market trading. INOVIO priced its $36 million underwritten offering of 2,536,258 common stock at $7.693 per share.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldi#NASDAQ">CLDI</a>) fell 18.3% to $0.49 in pre-market trading after dipping around 14% on Monday.</li>
<li>Qilian International Holding Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qli#NASDAQ">QLI</a>) fell 10.3% to $0.6220 in pre-market trading after declining around 8% on Monday.</li>
<li>Enservco Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensv#NASDAQ">ENSV</a>) fell 10.7% to $0.2820 pre-market trading. Enservco recently posted a wider-than-expected quarterly loss.</li>
<li>&nbsp;</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) fell 10.1% to $1.34 in pre-market trading after declining around 6% on Monday. The company recently announced the acquisition of AutoMax.</li>
<li>&nbsp;</li>
<li>U.S. Energy Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/useg#NASDAQ">USEG</a>) shares fell 9.3% to $1.25 in pre-market trading after gaining around 7% on Monday.</li>
<li>Addex Therapeutics Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adxn#NASDAQ">ADXN</a>) declined 9.1% to $22.50 in pre-market trading after falling around 3% on Monday.</li>
<li>Groupon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grpn#NASDAQ">GRPN</a>) shares fell 8.9% to $9.11 in pre-market trading. Groupon said Italian tax authorities have placed a lien on Groupon S.r.l.&#39;s bank account, which currently restricts outgoing payments from that account.</li>
<li>Live Nation Entertainment, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lyv#NYSE">LYV</a>) fell 7.8% to $92.02 pre-market trading following a report indicating the Justice Department will file an antitrust lawsuit against the company.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38263260/bank-of-america-morgan-stanley-and-3-stocks-to-watch-heading-into-tuesday"> Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday</a>

<h3>Gainers</h3>
<ul>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares rose 23.48% to $1.63. The market value of their outstanding shares is at $11.0 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 23.0% to $0.14. The company's market cap stands at $1.6 million. </li>
<li>Cullinan Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) shares moved upwards by 20.89% to $20.01. The company's market cap stands at $861.6 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock moved upwards by 18.85% to $76.97. The market value of their outstanding shares is at $7.4 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares moved upwards by 15.07% to $0.85. The market value of their outstanding shares is at $5.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares fell 24.3% to $8.32 during Tuesday's pre-market session. The company's market cap stands at $194.4 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 22.5% to $0.47. The market value of their outstanding shares is at $16.5 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) stock decreased by 20.06% to $0.24. The market value of their outstanding shares is at $1.5 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares declined by 12.69% to $21.61. The company's market cap stands at $22.8 million. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares fell 12.66% to $2.12. The market value of their outstanding shares is at $204.7 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares decreased by 10.38% to $1.21. The company's market cap stands at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

ALZN

BRTX

DRMA

ONVO

PSTX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Tuesday.
Shares of Live Nation Entertainment, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lyv#NYSE">LYV</a>) fell sharply in today&rsquo;s pre-market trading following a report indicating the Justice Department will file an antitrust lawsuit <a href="https://www.benzinga.com/quote/LYV/analyst-ratings">against the company</a>.
Live Nation Entertainment shares dipped 7.8% to $92.02 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Inovio Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ino#NASDAQ">INO</a>) shares dipped 24.3% to $8.32 in pre-market trading. INOVIO priced its $36 million underwritten offering of 2,536,258 common stock at $7.693 per share.</li>
<li>Groupon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grpn#NASDAQ">GRPN</a>) shares declined 8.9% to $9.11 in pre-market trading. Groupon said Italian tax authorities have placed a lien on Groupon S.r.l.&#39;s bank account, which currently restricts outgoing payments from that account.</li>
<li>Lyell Immunopharma Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyel#NASDAQ">LYEL</a>) shares fell 7.1% to $2.23 in pre-market trading after dipping 20% on Monday.</li>
<li>ArcelorMittal SA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mt#NYSE">MT</a>) shares fell 6% to $25.33 in pre-market trading after Deutsche Bank downgraded the stock from Buy to Hold.</li>
<li>Tevogen Bio Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvgn#NASDAQ">TVGN</a>) shares declined 6% to $2.21 in pre-market trading following a 4% decline on Monday.</li>
<li>Lennox International Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lii#NYSE">LII</a>) shares fell 5.8% to $434.82 in pre-market trading. Lennox is expected to report first quarter 2024 financial results before the opening bell on April 24, 2024.</li>
<li>Clean Energy Fuels Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clne#NASDAQ">CLNE</a>) shares declined 5.6% to $2.20 in pre-market trading after falling around 5% on Monday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38263545/johnson-johnson-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-"> Johnson &amp; Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#39;s Most Accurate Analysts</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

CLNE

LYEL

TVGN

Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

INOVIO&nbsp;Pharmaceuticals announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of&nbsp;$7.693&nbsp;per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of&nbsp;$7.692&nbsp;per pre-funded warrant, in each case before underwriting discounts and commissions.&nbsp;

Reported Earlier, INOVIO Prices $36M Underwritten Offering Of 2,536,258 Common Stock At $7.693/Share

<a href="https://twitter.com/DrTedros/status/1778423967105139108">https://twitter.com/DrTedros/status/1778423967105139108</a>
&nbsp;
&nbsp;

Biotech

Global

General

AEMD

CMRX

GOVX

MRNA

SIGA

TNXP

WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. </li>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock increased by 6.79% to $1.1. The market value of their outstanding shares is at $248.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 10.3% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $81.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 4.9% to $0.02. The market value of their outstanding shares is at $1.1 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock fell 4.82% to $1.78. The market value of their outstanding shares is at $322.6 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 4.7% to $1.42. The company's market cap stands at $69.6 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 4.63% to $2.06. The market value of their outstanding shares is at $140.4 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock declined by 4.33% to $12.03. The market value of their outstanding shares is at $623.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ATNF

CERS

ELTX

ETAO

GOSS

LGVN

MNOV

SINT

STOK

12 Health Care Stocks Moving In Friday's After-Market Session

Inovio Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INO#NYSE">INO</a>) short percent of float has risen 22.31% since its last report. The company recently reported that it has 1.74 million shares sold short, which is 7.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Inovio Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1710164715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Inovio Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Inovio Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Inovio Pharmaceuticals's peer group average for short interest as a percentage of float is 8.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Inovio Pharmaceuticals's Recent Short Interest

Oppenheimer analyst Hartaj Singh maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Outperform and maintains $40 price target.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Maintains $40 Price Target

RBC Capital analyst Gregory Renza reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Sector Perform and maintains $11 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Inovio Pharmaceuticals, Maintains $11 Price Target

On Wednesday, U.S. indices closed positively as the Dow Jones Industrial Average edged up by 0.2% to reach 38,661.05. Meanwhile, the S&amp;P 500 experienced a slight rise of 0.5%, settling at 5,104.76, whereas the Nasdaq rose by 0.6% to hit 16,031.54.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) saw a notable performance today, closing up 1.96% at $9.87. The stock reached an intraday high of $10.31 and a low of $9.67, with a 52-week range between $15.73 and $3.89. Inovio <a href="https://www.benzinga.com/insights/earnings/24/03/37522363/recap-inovio-pharmaceuticals-q4-earnings">outperformed earnings expectations</a> by 13.0%, reporting an EPS of $-1.1 against an estimate of $-1.27, despite a slight decrease in revenue from the previous year.
Victoria&#8217;s Secret &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) experienced a downturn, closing down 3.86% at $25.62. The stock&#8217;s intraday movements were between $26.98 and $24.9, with its 52-week range from $35.85 to $13.62. The company reported fourth-quarter<a href="https://www.benzinga.com/news/earnings/24/03/37522113/victorias-secret-stock-is-spiraling-lower-whats-going-on"> earnings</a> with a slight miss on revenue forecasts but exceeded EPS expectations, alongside announcing a new share repurchase program of up to $250 million.
Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) ended the day slightly higher by 0.54% at $1350. The stock hit a high of $1394.83 and a low of $1347.06 during the day, with its 52-week high at $1438.17 and low at $601.29. Broadcom is anticipated to report strong first-quarter<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37509424/broadcoms-strong-technical-setup-bullish-trend-ahead-of-earnings"> earnings</a>, buoyed by its position within the AI5 group of stocks, showcasing a bullish technical setup ahead of its earnings announcement.
Aptorum Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) surged 1.43% to close at $0.71. Throughout the day, shares fluctuated between $0.72 and $0.68, while its 52-week range has been between $1.07 and $0.53. The company announced a <a href="https://www.benzinga.com/general/biotech/24/03/37515677/oncology-and-infectious-diseases-focused-aptorum-stock-skyrockets-7x-on-wednesday-heres-why">merger agreement</a> with YOOV Group, signaling a significant restructuring process and a promising future in AI and automation for business operations.
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) declined by 2.32% to end at $176.54. The electric vehicle giant saw an intraday high of $181.58 and a low of $173.7, with its 52-week range spanning from $299.29 to $152.37. Morgan Stanley analyst Adam Jonas highlighted <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37501204/tesla-faces-uphill-battle-morgan-stanley-analyst-adam-jonas-cuts-target-price-forec">several challenges</a> facing Tesla, including dwindling EV demand and heavy competition, leading to a cut in the target price and FY24 earnings estimates. Despite these challenges, Tesla is still seen as a potential leader in AI, pending the stabilization of its auto earnings.
Photo by WHYFRAME on Shutterstock
Prepare for the day's trading <a href="https://wordhtml.com/Premarket%20Movers%20&amp;%20News%20&#x2A;&#x2A;">with top premarket movers and news</a> by Benzinga.
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Equities

AVGO

TSLA

VSCO

Victoria's Secret, Inovio Pharmaceuticals, Broadcom, Aptorum Group, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) reported its Q4 earnings results on Wednesday, March 6, 2024 at 06:30 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Inovio Pharmaceuticals beat estimated earnings by 13.0%, reporting an EPS of $-1.1 versus an estimate of $-1.27.
Revenue was down $22 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 4.0% drop in the share price the next day.
Here's a look at Inovio Pharmaceuticals's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.56</td>
<td>-1.68</td>
<td>-1.68</td>
<td>-2.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.56</td>
<td>-1.56</td>
<td>-1.92</td>
<td>-2.64</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>120K</td>
<td>260K</td>
<td>270K</td>
<td>340K</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>388K</td>
<td>225K</td>
<td>114K</td>
<td>125K</td>
</tr>
</tbody>
</table>

To track all earnings releases for Inovio Pharmaceuticals <a href="https://www.benzinga.com/quote/INO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Inovio Pharmaceuticals Q4 Earnings

Guidance

INOVIO Pharmaceuticals Expects Cash Runway To Extend Into Q2 2025

Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) reported quarterly losses of $(1.100) per share which beat the analyst consensus estimate of $(1.270) by 13.39 percent. The company reported quarterly sales of $103.000 thousand which missed the analyst consensus estimate of $344.200 thousand by 70.08 percent. This is a 17.60 percent decrease over sales of $125.000 thousand the same period last year.

Earnings Beats

Earnings Misses

Inovio Pharmaceuticals Q4 2023 GAAP EPS $(1.100) Beats $(1.270) Estimate, Sales $103.000K Miss $344.200K Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
&bull; Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion.
&bull; JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is likely to report quarterly earnings at $0.63 per share on revenue of $42.16 billion.
&bull; Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $326.63 million.
&bull; Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report earnings for its fourth quarter.
&bull; Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $2.27 billion.
&bull; Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $86.80 million.
&bull; VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $22.43 million.
&bull; Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is expected to report quarterly earnings at $2.83 per share on revenue of $1.43 billion.
&bull; Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $1.12 billion.
&bull; WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is likely to report quarterly loss at $0.23 per share on revenue of $19.86 million.
&bull; Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) is projected to report earnings for its fourth quarter.
&bull; iShares $ Short Duration Corp Bond UCITS ETF USD (Dist) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDIG#NASDAQ">SDIG</a>) is projected to report quarterly loss at $0.98 per share on revenue of $22.21 million.
&bull; InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $1.63 million.
&bull; Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $658.50 million.
&bull; Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $37.71 million.
&bull; PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) is projected to report quarterly loss at $0.23 per share on revenue of $180 thousand.
&bull; Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $43.55 million.
&bull; Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is expected to report quarterly loss at $0.07 per share on revenue of $126.13 million.
&bull; Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $20.47 million.
&bull; NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is estimated to report quarterly loss at $4.16 per share on revenue of $283.44 million.
&bull; Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $2.44 billion.
&bull; EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is projected to report quarterly loss at $0.18 per share on revenue of $44.03 million.
&bull; Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is estimated to report quarterly loss at $2.01 per share on revenue of $55.25 million.
&bull; BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) is expected to report quarterly loss at $0.01 per share on revenue of $8.42 million.
&bull; Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $1.75 million.
&bull; European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $54.08 million.
&bull; REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $579.42 million.
&bull; United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) is likely to report quarterly loss at $0.01 per share on revenue of $7.87 billion.
&bull; Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $182.37 million.
&bull; Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter.
&bull; Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) is estimated to report quarterly earnings at $0.54 per share on revenue of $46.42 million.
&bull; Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) is expected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $144.29 million.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Fortuna Silver Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $261.00 million.
&bull; Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $1.27 per share on revenue of $340 thousand.
&bull; Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $2.32 billion.
&bull; Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; TDCX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDCX#NYSE">TDCX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $121.92 million.
&bull; Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $440.69 million.
&bull; VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) is expected to report quarterly earnings at $0.75 per share on revenue of $234.91 million.
&bull; Victoria&#39;s Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is projected to report quarterly earnings at $2.47 per share on revenue of $2.09 billion.
&bull; SandRidge Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SD#NYSE">SD</a>) is likely to report earnings for its fourth quarter.
&bull; CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is projected to report earnings for its fourth quarter.
&bull; Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is expected to report quarterly loss at $0.23 per share on revenue of $61.45 million.
&bull; KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $212.97 million.
&bull; Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly loss at $0.16 per share on revenue of $59.49 million.
&bull; GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $43.95 million.
&bull; MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $174.28 million.
&bull; IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is projected to report earnings for its second quarter.
&bull; FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is projected to report earnings for its fourth quarter.
&bull; Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $12.00 million.
&bull; NeoGames (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) is projected to report quarterly loss at $0.07 per share on revenue of $54.53 million.
&bull; Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) is estimated to report earnings for its fourth quarter.
&bull; Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $76.22 million.
&bull; Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is likely to report quarterly loss at $0.09 per share on revenue of $421.19 million.
&bull; Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $280 thousand.
&bull; Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is expected to report quarterly loss at $0.12 per share on revenue of $70 thousand.
&bull; HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $339.52 million.
&bull; BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $123.75 million.
&bull; MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) is likely to report quarterly loss at $0.11 per share on revenue of $18.14 million.
&bull; NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is estimated to report earnings for its fourth quarter.
&bull; Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $260.16 million.
&bull; Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $43.57 million.
&bull; OneSpan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSPN#NASDAQ">OSPN</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $58.26 million.
&bull; Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $84.14 million.
&bull; SilverCrest Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SILV#AMEX">SILV</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $7.93 million.
&bull; comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $97.69 million.
&bull; Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.00 million.
&bull; Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is projected to report earnings for its third quarter.
&bull; ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $20.98 million.
&bull; Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is projected to report earnings for its fourth quarter.
&bull; Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter.
&bull; OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is expected to report quarterly loss at $0.28 per share on revenue of $37.73 million.
&bull; Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is estimated to report earnings for its fourth quarter.
&bull; Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $40.28 million.
&bull; Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) is projected to report earnings for its fourth quarter.
&bull; Airgain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRG#NASDAQ">AIRG</a>) is projected to report quarterly loss at $0.20 per share on revenue of $10.00 million.
&bull; Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is projected to report quarterly loss at $0.08 per share on revenue of $63.22 million.
&bull; Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $100.24 million.
&bull; TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $33.13 million.
&bull; CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $96.49 million.
&bull; Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $222.52 million.
&bull; Cyber Hornet S&amp;P 500 and Bitcoin 75/25 Strategy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZZZ#NASDAQ">ZZZ</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $247.43 million.
&bull; Ellington Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $2.46 million.
&bull; Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is expected to report quarterly loss at $0.72 per share on revenue of $29.34 million.
&bull; Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $73.40 million.
&bull; Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) is likely to report quarterly loss at $0.03 per share on revenue of $178.56 million.
&bull; Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.30 million.
&bull; Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $437.34 million.
&bull; Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is estimated to report quarterly earnings at $1.60 per share on revenue of $94.75 million.
&bull; Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is expected to report quarterly loss at $0.43 per share on revenue of $15.45 million.
&bull; Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is projected to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADAP

AEYE

AIRG

AMPY

ARIS

BRCC

BWAY

CDXC

CMPO

CPSH

CULP

DSGX

EARN

EHAB

EVGO

EWCZ

FRPH

GENI

GENK

GROV

GWRS

HDSN

HIPO

HNST

HTOO

INFN

KEQU

KIDS

KLXE

KMDA

LVLU

MDXH

NEUE

NEXN

NGMS

NSPR

OSPN

PowerShares Insured Municipal Bond Portfolio

REPX

REVG

SCOR

SDIG

SGHC

SILV

SLNG

SOHO

SPIR

TDCX

TLPH

TPVG

TRIN

UNFI

VBNK

VSEC

XERS

YEXT

ZYME

Earnings Scheduled For March 6, 2024

Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Here's what investors need to know before the announcement.
Analysts estimate that Inovio Pharmaceuticals will report an earnings per share (EPS) of $-1.27. 
Inovio Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 3.67% drop in the share price the next day.
Here's a look at Inovio Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.56</td>
<td>-1.68</td>
<td>-1.68</td>
<td>-2.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.56</td>
<td>-1.56</td>
<td>-1.92</td>
<td>-2.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>13.0%</td>
<td>-3.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709661699_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Inovio Pharmaceuticals were trading at $9.82 as of March 04. Over the last 52-week period, shares are down 33.35%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/INO/earnings">To track all earnings releases for Inovio Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Inovio Pharmaceuticals's Earnings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inovio Pharmaceuticals Stock (NASDAQ:INO), Short Interest Report

People Also Watch